We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

35 hedge funds and large institutions have $16.2M invested in Xilio Therapeutics in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.17% more ownership

Funds ownership: 3.11% → 3.28% (+0.17%)

0% more funds holding

Funds holding: 35 → 35 (0)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

1% less capital invested

Capital invested by funds: $16.3M → $16.2M (-$139K)

64% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 11

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
0.46%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
5
Increased
4
Reduced
11
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCM
Ghisallo Capital Management
Massachusetts
+$1.01M
2
Morgan Stanley
Morgan Stanley
New York
+$218K
3
Squarepoint
Squarepoint
New York
+$178K
4
UBS Group
UBS Group
Switzerland
+$58K
5
XT
XTX Topco
Cayman Islands
+$26.2K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$281K
2
BlackRock
BlackRock
New York
-$54.8K
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$41.9K
4
Millennium Management
Millennium Management
New York
-$37K
5
SRL
Scientech Research LLC
New Jersey
-$30.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Raymond James Financial
26
Raymond James Financial
Florida
$12.8K -$11.5K -1,086 -45%
TRCT
27
Tower Research Capital (TRC)
New York
$10.5K +$11.6K +1,101 New
DF
28
Dunhill Financial
United Kingdom
$6.99K – – –
IAMOG
29
Investors Asset Management of Georgia
Georgia
$6.8K – – –
PFG
30
Pinnacle Financial Group
Illinois
$6.8K – – –
FDCDDQ
31
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.24K – – –
BlackRock
32
BlackRock
New York
$1.39K -$54.8K -5,190 -97%
KFI
33
Key Financial Inc
Pennsylvania
$564 – – –
Bank of America
34
Bank of America
North Carolina
$225 +$32 +3 +14%
PWMG
35
Private Wealth Management Group
New Jersey
$211 – – –
Millennium Management
36
Millennium Management
New York
– -$37K -3,651 Closed
SRL
37
Scientech Research LLC
New Jersey
– -$30.8K -3,039 Closed
ACM
38
ADAR1 Capital Management
Texas
– -$29K -2,857 Closed
SPIA
39
Steward Partners Investment Advisory
New York
– -$14.5K -1,429 Closed
JP Morgan Chase
40
JP Morgan Chase
New York
– -$45 -4 Closed
1
2

XLO Hedge Fund Activity: Q2 2025 in Review

35 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2025, worth a combined $16.2M — down 0.85% from $16.3M a quarter earlier.

Fund positioning in XLO was balanced in Q2 2025: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 11 trimmed.

The largest buyer was Ghisallo Capital Management, opening a new position worth an estimated $1.01M. The largest seller was Fidelity Investments, cutting an estimated $281K.

  • 35 institutional investors held Xilio Therapeutics (XLO) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $16.2M of Xilio Therapeutics stock for Q2 2025, down 0.85% quarter-over-quarter.
  • 5 funds opened new Xilio Therapeutics positions in Q2 2025 and 5 closed out, a net change of 0 holders.
  • The largest Xilio Therapeutics buyer in Q2 2025 was Ghisallo Capital Management, an estimated $1.01M added.
  • The largest Xilio Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $281K sold.

Based on aggregated 13F filings for Q2 2025.